like_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":699023724,"tweetId":"699023724","gmtCreate":1639725404735,"gmtModify":1639725404995,"author":{"id":3582720098998598,"idStr":"3582720098998598","authorId":3582720098998598,"authorIdStr":"3582720098998598","name":"newcomer676","avatar":"https://static.tigerbbs.com/915835840baa58cd8ff045fc189b3a3f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":21,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>like</body></html>","htmlText":"<html><head></head><body>like</body></html>","text":"like","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/699023724","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","kind":"news","pubTimestamp":1639724439,"share":"https://www.laohunote.com/m/news/1131183374?lang=zh_CN&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.<blockquote>两家生物技术公司周四开始交易。一个跳了下去，另一个跳了下去。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.<blockquote>生物技术公司 Immix Biopharma 的股价较发行价下跌近 27%，IPO 市场将在 2021 年戛然而止。</blockquote> Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.<blockquote>Immix（股票代码：IMMX）是本周第三家股价低于首次公开募股价格的公司。周三，生物技术公司 Genenta Science (GNTA) 下跌超过 4%，而低碳水化合物葡萄酒生产商 Fresh Vine Wine (Vine) 前一天暴跌近 30%。</blockquote> Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.<blockquote>Bionomics (BNOX) 周四也开盘，股价上涨超过 19%。该生物技术公司不被视为首次公开募股，因为其股票已经在澳大利亚证券交易所交易。</blockquote> IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.<blockquote>12月份IPO大幅放缓。Dealogic 表示，本月已有 10 家公司通过传统 IPO 上市，筹集了 49 亿美元。相比之下，去年有 21 家公司使用传统发行方式上市，筹集了 128 亿美元。</blockquote> The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.<blockquote>IPO市场预计将于下周因假期休市，许多交易将被搁置。新刊预计将于一月中旬重新发行。预计周五不会有公司使用传统发行方式上市。</blockquote> Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.<blockquote>包括 Immix 和 Bionomics 在内的六家公司本周已对其交易进行了定价。卫星公司 Sidus Space (SIDU) 表现强劲，其股价周二飙升近 144%。周三，物联网公司Samsara（IOT）的股票上涨超过7%。</blockquote> Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.<blockquote>Immix 股价开盘价为 5 美元，随后下跌。该股收于 3.67 美元，较发行价下跌 1.33 美元。</blockquote> Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.<blockquote>Immix正在开发组织特异性疗法来治疗癌症和炎症。招股说明书称，其主要候选产品IMX-110目前正在美国和澳大利亚进行针对实体瘤的1b/2a期临床试验。</blockquote> Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.<blockquote>Immix 将交易规模增加到 420 万美元，并以每股 5 美元的价格出售。这家洛杉矶公司原计划以每股 5 至 6 美元的价格出售约 383 万股股票。</blockquote> Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.<blockquote>与此同时，Bionomcis 的股价开盘价为 22 美元，收盘价为 14.73 美元，较发行价上涨 2.38 美元。</blockquote> Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.<blockquote>生物学正在为患有严重中枢神经系统疾病的人开发治疗方法。根据招股说明书，其主要候选产品 BNC210 可治疗社交焦虑症和创伤后应激障碍。</blockquote> Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.<blockquote>Bionomics 以每股 12.35 美元的价格出售了 162 万股美国存托股 (ADS)。每股美国存托凭证代表180股Bionomics普通股。</blockquote>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.<blockquote>两家生物技术公司周四开始交易。一个跳了下去，另一个跳了下去。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.<blockquote>两家生物技术公司周四开始交易。一个跳了下去，另一个跳了下去。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-12-17 15:00\n\n</h4>\n</header>\n<article>\nThe IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.<blockquote>生物技术公司 Immix Biopharma 的股价较发行价下跌近 27%，IPO 市场将在 2021 年戛然而止。</blockquote> Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.<blockquote>Immix（股票代码：IMMX）是本周第三家股价低于首次公开募股价格的公司。周三，生物技术公司 Genenta Science (GNTA) 下跌超过 4%，而低碳水化合物葡萄酒生产商 Fresh Vine Wine (Vine) 前一天暴跌近 30%。</blockquote> Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.<blockquote>Bionomics (BNOX) 周四也开盘，股价上涨超过 19%。该生物技术公司不被视为首次公开募股，因为其股票已经在澳大利亚证券交易所交易。</blockquote> IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.<blockquote>12月份IPO大幅放缓。Dealogic 表示，本月已有 10 家公司通过传统 IPO 上市，筹集了 49 亿美元。相比之下，去年有 21 家公司使用传统发行方式上市，筹集了 128 亿美元。</blockquote> The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.<blockquote>IPO市场预计将于下周因假期休市，许多交易将被搁置。新刊预计将于一月中旬重新发行。预计周五不会有公司使用传统发行方式上市。</blockquote> Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.<blockquote>包括 Immix 和 Bionomics 在内的六家公司本周已对其交易进行了定价。卫星公司 Sidus Space (SIDU) 表现强劲，其股价周二飙升近 144%。周三，物联网公司Samsara（IOT）的股票上涨超过7%。</blockquote> Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.<blockquote>Immix 股价开盘价为 5 美元，随后下跌。该股收于 3.67 美元，较发行价下跌 1.33 美元。</blockquote> Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.<blockquote>Immix正在开发组织特异性疗法来治疗癌症和炎症。招股说明书称，其主要候选产品IMX-110目前正在美国和澳大利亚进行针对实体瘤的1b/2a期临床试验。</blockquote> Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.<blockquote>Immix 将交易规模增加到 420 万美元，并以每股 5 美元的价格出售。这家洛杉矶公司原计划以每股 5 至 6 美元的价格出售约 383 万股股票。</blockquote> Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.<blockquote>与此同时，Bionomcis 的股价开盘价为 22 美元，收盘价为 14.73 美元，较发行价上涨 2.38 美元。</blockquote> Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.<blockquote>生物学正在为患有严重中枢神经系统疾病的人开发治疗方法。根据招股说明书，其主要候选产品 BNC210 可治疗社交焦虑症和创伤后应激障碍。</blockquote> Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.<blockquote>Bionomics 以每股 12.35 美元的价格出售了 162 万股美国存托股 (ADS)。每股美国存托凭证代表180股Bionomics普通股。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1,"symbols_score_info":{"BNOX":0.9,"IMMX":0.9}},"isVote":1,"tweetType":1,"viewCount":1351,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/699023724"}